Topic Listing for Geron

Access Necessary Tissue Samples Information Licensed Technologies Restricted Accrued Liabilities
Acquired In-process Research Technology Acquisition In-process Research Technology
Act 1934 Activities Involve Hazardous Materials Improper Handling Employees Agents
Additional Factors Affect Future Results Additional Option Grant Director
Adjustments Changes Capitalization Corporate Transactions Administration
Administration Grants Awards Plan Affiliations
Agreement Agriculture
Alan Colowick Mph Alexander Barkas Phd
Alliance Workplan Amendment Employment Agreement
Amendment Termination Plan Amendment Termination Purchase Plan
Annual Incentive Awards Approval Amendment 1996 Employee Stock Purchase Plan
Approval Amendments 2006 Directors Stock Option Plan Arbitration Procedure
Assignability Assignment Form
Assistance Questions Attestation Report Independent Registered Public Accounting Firm
Audit Committee Audit Committee Report
Audit Fees Other Automatic Grant Program
Automatic Withdrawal Award Agreement
Base Salary Basis Presentation
Because Collaborators Obtain Regulatory Approval Market Products United Because Collaborators Obtain Regulatory Approvals Market Products United
Behrs Beneficial Ownership Reporting Compliance
Board Board Committees Meetings
Board Directors Business Early Stage Development
Business Overview Calvin Harley Phd
Cancer Diagnostics Cancer Diagnostics Telomerase Plus Test
Cancer Diagnostics Telomerase Plus Test Tbt Cancer Therapeutics Diagnostics
Cardiomyocytes Heart Disease Cardiomyocytes Heart Disease Grncm1
Cash Equivalents Marketable Debt Securities Available-for-sale Cash Equivalents Marketable Securities
Cash Equivalents Marketable Securities Available-for-sale Cash Flows Financing Activities
Cash Flows Investing Activities Cash Flows Operating Activities
Cause Cell Bank Costs
Certain Definitions Certain Provisions Delaware Law Charter Bylaws
Certain Relationships Related Transactions Certain Transactions
Certification Pursuant Form Rule 13a-14 15d-14 Adopted 302 Certification Pursuant Form Rule 13a-14 Adopted 302 Sarbanes-oxley
Certification Pursuant Usc 1350 Adopted 906 Sarbanes-oxley Certification Pursuant Usc 1350 Adopted 906 Sarbanes-oxley Act
Challenges Patent Rights Result Costly Time-consuming Legal Proceedings Change Control
Changes Internal Controls Changes Internal Controls Over Financial Reporting
Changes Level Recurring Fair Value Measurements Charles Homcy
Chief Executive Officer Other Officers Compensation Chondrocytes Osteoarthritis
Claims Procedure Class Directors Term Expiring 2006 Annual Meeting
Class Directors Term Expiring 2007 Annual Meeting Class Directors Term Expiring 2008 Annual Meeting
Class Directors Term Expiring 2009 Annual Meeting Class Directors Term Expiring 2010 Annual Meeting
Class Directors Term Expiring 2011 Annual Meeting Class Directors Term Expiring 2012 Annual Meeting
Classified Board Directors Clinical Development
Closing Delivery Common Stock Warrants Code Conduct
Code Ethics Collaborative Agreement
Collaborative Agreements Commissions Discounts
Common Stock Common Stock Reserved Future Issuance
Comparable Employment Comparison Cumulative Total Return Investment Among Geron Corporation
Compensation Committee Compensation Committee Interlocks Insider Participation
Compensation Committee Report Compensation Committee Role
Compensation Decisions Compensation Elements Purpose
Compensation Executive Officers Compliance
Compliance Internal Revenue Code 162 Comprehensive Income Loss
Comprehensive Loss Concentrations Customers Suppliers
Condensed Consolidated Statements Cash Flows Data Conditions Gerons Obligations Closings
Conditions Issuance Shares Conference Call Video Webcast Set 600 Pst 900
Consent Independent Registered Public Accounting Firm Consolidated Financial Statements
Consolidated Statements Cash Flows Consolidated Statements Operations
Consolidation Merger Sale Assets Constitution Drive Menlo Park 94025
Contractual Obligations Contribution Agreement
Contribution Stock Issuance Shares Controls Procedures
Conversion Expense Conversion Rights
Convertible Debentures Corporate Development
Corporate Governance Corporate Information
Covenants Credit Risk
Critical Accounting Policies Estimates Current Report Pursuant Securities Exchange Act 1934
David Earp Phd David Greenwood
Debt Securities Common Stock Preferred Warrants Deemed Dividend Derivatives
Defeasance Debt Securities Certain Covenants Circumstances Definitions
Delays Commencement Clinical Testing Current Potential Product Candidates Delivery
Dendritic Cells Cancer Immunotherapy Enable Therapeutic Graft Acceptance Departure Directors Certain Officers Election Appointment Compensatory
Departure Directors Principal Officers Election Appointment Depend Collaborators Help Complete Process Developing Testing Products
Depend Collaborators Joint Venture Partners Help Develop Test Depend Other Parties Help Develop Manufacture Test Product
Depreciation Amortization Derivative Financial Instruments
Derivatives Description Preferred Stock
Directors Executive Officers Corporate Governance Directors Executive Officers Registrant
Directors Stock Option Plan Dividend Policy
Documents Incorporated Reference Duration Termination
Edward Fritzky Effect Acquisition
Effect Certain Corporate Events Effective Date
Election Directors Eligibility
Email Employee Stock Plans
Employee Stock Purchase Plan Employees
Employment Agreements Severance Plan End Results
Enforce Rights Enhanced Severance
Entry Clinical Trials Product Candidates Not Result Commercially Entry Clinical Trials Products Not Result Commercially Viable
Entry Material Definitive Agreement Equipment Line
Equipment Loans Equity Awards
Equity Compensation Plans Equity Grant Practices Vesting Conditions
Equity Incentive Plan Equity Investments Licensees
Erisa Estimates
Ethical Legal Social Implications Research Using Embryonic Stem European Economic Area
European Other Regulatory Approval Evaluation Disclosure Controls Procedures
Events Default Exact Name Registrant Specified Charter
Exchange Transfer Exclusive License Alliance Agreement
Executive Compensation Executive Compensation Philosophy
Executive Officers Executive Vice President Chief Financial Officer
Exercise Option Exercise Price Consideration
Exercise Price Term Options Exhibits
Exhibits Financial Statement Schedules Explanatory
Fabio Benedetti Fabio Benedetti Appointed Chief Medical Officer Oncology
Fail Meet Obligations License Agreements Face Loss Rights Fail Meet Obligations License Agreements Lose Rights Key
Fail Obtain Acceptable Prices Adequate Reimbursement Product Candidates Failure Achieve Maintain Effective Internal Controls Accordance 404
Fair Value Derivatives Fair Value Financial Instruments
Fair Value Measurements Fair Value Recurring Basis
Fda Approval Process Fda Places Geron8217s Grnopc1 Ind Clinical Hold
Federal Income Tax Aspects Fees
Finance Legal Administration Financial Statement Schedules
Financial Statements Exhibits Financial Statements Schedules
Foreign Currency Exchange Risk Form 10-k
Form 10-q Form 8-k
Form Assignment Form Common Stock Warrant Purchase Agreement
Form Exercise Agreement Form Lock-up Agreement
Form Warrant Former Name Address Changed Since Last Report
Forward-looking Statements Funds
Gehc Exceptions General
General Administrative Expenses General Eligibility
General Purpose Geron
Geron Appoints Audit Committee Members Geron Appoints Stephen Kelsey Executive Vice President Chief
Geron Corporation Geron Corporation 1996 Employee Stock Purchase Plan Amended
Geron Corporation 2005 Annual Meeting Stockholders Geron Corporation 2007 Annual Meeting Stockholders
Geron Corporation 2008 Annual Meeting Stockholders Geron Corporation Announces Pricing Common Stock Offering
Geron Corporation Condensed Consolidated Statements Operations Except Share Geron Corporation Notes Condensed Consolidated Financial Statements 2009
Geron Corporation Reports 2008 Financial Results Events Geron Corporation Reports 2009 Financial Results Events
Geron Corporation Reports Annual 2007 Financial Results Highlights Geron Corporation Reports Annual 2008 Financial Results Highlights
Geron Exeter Life Sciences Merge Start Licensing Viagen Geron Fda Reach Agreement Clinical Hold
Geron Plan Participants Geron Receives Fda Clearance Begin World8217s Human Clinical
Geron Reports 2008 Financial Results Geron8217s Ind Spinal Cord Injury Placed Hold
Global Securities Governing Law
Government Regulation Greement
Healthcare Healthcare Geron Announce Exclusive Global Agreement Commercialize Stem
Healthcare Limited Held 2009
Hematopoietic Cells Hematologic Diseases Prevent Immune Rejection Hereas
Herefore Hereof
Highlights Hiv Aids
Householding Annual Meeting Materials Http Wwwgeroncom Showpageaspcodecorpdi
Human Embryonic Stem Cell Therapeutics Human Embryonic Stem Cell Therapies
Human Embryonic Stem Cells Human Embryonic Stem Cells Potential Source Manufacturing Replacement
Human Embryonic Stem Cells Potential Source Manufacturing Therapeutic Identification Directors
Identification Executive Officers Immortalized Cells Research
Impairment Intellectual Property Rights Adversely Affect Value Technologies Impairment Intellectual Property Rights Limit Ability Pursue Development
Implications Executive Compensation Important Notice Regarding Availability Proxy Materials Annual Meeting
Income Taxes Indemnification
Indemnifications Officers Directors Index
Information Concerning Certain Executive Officers Intangible Asset Research Funding Obligation
Interest Interest Other Expense
Interest Other Income Interest Other Income Equity Losses Joint Venture
Interest Rate Sensitivity Internet Electronic Availability Proxy Materials
Investors Islet Cells Diabetes
Islet Cells Diabetes Grnic1 Issuance Exercise Merck Warrant
Jane Lebkowski Phd John Walker
Joint Press Release Joint Venture Related Party Transactions Start Licensing Viagen
Journal Immunology Journal Neuroscience
Karin Eastham Latham Watkins Letterhead
Latham Watkins Llp Lazard Capital Markets
Limitation Employee Rights At-will Employment Liquidity Capital Resources
List Subsidiaries Llp
Loan Long-term Incentive Awards
Loss Key Personnel Slow Ability Conduct Research Develop Loss Recognized Equity Method Investment
Losses Recognized Equity Method Investment Management Invest Spend Proceeds Offering Ways Not Agree
Management Report Internal Control Over Financial Reporting Managements Report Internal Control Over Financial Reporting
Market Information Market Registrants Common Stock Related Stockholder Matters
Marketable Debt Securities Available-for-sale Marketable Non-marketable Equity Investments Licensees
Marketable Non-marketable Equity Investments Licensees Joint Venture Marketable Non-marketable Equity Investments Licensees Joint Ventures
Marketable Non-marketable Investments Licensees Material Change Terms Employment
Meaning Present Fairly Conformity Generally Accepted Accounting Principles Melissa Kelly Behrs
Members Board Directors Continuing Office Menlo Park Calif 2009
Menlo Park California 94025 Merger Ahead Fda Report Concludes Food Products Cloned
Miscellaneous Miscellaneous Provisions
Modification Waiver Much Information Know-how Critical Business Not Patentable Able
Nature Biotechnology Need Additional Capital Conduct Operations Develop Product Candidates
Need Additional Capital Conduct Operations Develop Products Ability Need Additional Financing
Net Loss Net Loss Applicable Common Stockholders
Net Loss Per Share New Purchasers Common Stock Experience Immediate Substantial Dilution
Nominating Committee Nominee Class Director Term Expiring 2008 Annual Meeting
Non-qualified Deferred Compensation Nonqualified Deferred Compensation
Nontransferability Awards Not Able Obtain Maintain Sufficient Insurance Commercially Reasonable
Not Experience Conducting Large-scale Clinical Trials Other Areas Not Intend Pay Cash Dividends Common Stock Foreseeable
Notes Receivable Related Parties Notice Annual Meeting Stockholders Held 2005
Notice Annual Meeting Stockholders Held 2007 Notice Annual Meeting Stockholders Held 2008
Notices Nuclear Transfer
Nuclear Transfer Agriculture Xenotransplantation Biologics Number 0-20859
Objectives Executive Compensation Program Obtaining Regulatory Approvals Market Product Candidates United States
Offer Letter Between Geron Corporation Fabio Benedetti Dated Offering Common Stock Warrants
Offering Periods Purchase Oligodendrocyte Progenitor Cells Spinal Cord Injury Grnopc1
Oligodendrocytes Spinal Cord Injury Dopaminergic Neurons Parkinsons Disease Oligodendrocytes Spinal Cord Injury Grnopc1
Oncology Oncolytic Virus
Oncolytic Virus Ov1060 Cg5757 Operating Lease Commitment
Option Exercises Stock Awards Vested Option Grants
Organization Organization Summary Significant Accounting Policies
Osteoblasts Osteoporosis Non-union Bone Fractures Other Benefits
Other Events Other Fair Value Disclosures
Other Matters Other Recent Accounting Pronouncements
Other Regulations Over-allotment Option
Overview Page Geron Announces Direct Equity Issuance
Part Patents Proprietary Technology
Patrick Zenner Payment Interest Exchange
Payment Paying Agent Pension Benefits
Performance Graph Performance Measurement Comparison
Philosophy Plan
Plan Benefits Plan Distribution
Please Sign Date Return Proxy Card Enclosed Envelope Policies Procedures
Potential Payments Termination Change Control Potential Restrictions Ban Nuclear Transfer Prevent Benefiting Financially
Power Attorney President Chief Executive Officer
Price Stabilization Short Positions Passive Market Making Principal Accountant Fees Services
Principal Accounting Fees Services Principles Consolidation
Private Financings Pro Forma Information Sfas 123 Prior 2006
Pro Rata Product Development
Products Likely Expensive Manufacture They Not Profitable Unable Products Research Development
Promissory Properties
Property Equipment Proposed Amendments
Provided However Provisions Share Purchase Rights Plan Charter Bylaws Delaware
Prudent Actions Plan Fiduciaries Public Attitudes Towards Gene Therapy Negatively Affect Regulatory
Public Offering Public Offering Concurrent Warrant Exercise
Purchase Form Purchase Price
Purchase Provisions Purchase Sale Common Stock Warrants
Purchases Equity Securities Issuer Affiliated Purposes Plan
Pursuant Securities Exchange Act 1934 Quantitative Qualitative Disclosures Market Risk
Quarterly Results Quorum Requirement Votes Required Proposals
Rank Ratification Selection Independent Auditors
Ratification Selection Independent Registered Public Accounting Firm Receive Information Plan Benefits
Recent Accounting Pronouncements Recent Sales Unregistered Securities
Recently Issued Accounting Guidance Recitals
Reclassifications Redemption
Regarding Trustee Regulatory Agency Define Path Re-initiate Human Trials Spinal
Reimbursement Status Newly-approved Health Care Products Uncertain Failure Reliance Activities Non-employee Consultants Research Institutions Scientific Contractors
Reliance Research Activities Non-employee Scientific Advisors Other Institutions Remainder Page Intentionally Left Blank Signature Follows
Remediation Steps Address Material Weakness Report Independent Registered Public Accounting Firm
Reports Representations Acknowledgments Investors
Representations Warranties Representations Warranties Geron
Representations Warranties Viagen Required Vote
Research Development Expenses Reservation Shares
Restatement Consolidated Financial Statements Restricted Cash
Restricted Stock Restricted Stock Awards
Restricted Stock Units Restrictions Resale Shares
Results Operations Results Operations Financial Condition
Revenue Recognition Revenues
Revocability Proxies Rights Erisa
Risks Related Business Risks Related Business Early Stage Development
Risks Related Clinical Commercialization Activities Risks Related Common Stock Financial Reporting
Risks Related Competitive Factors Risks Related Environmental Product Liability
Risks Related Financial Position Need Additional Financing Risks Related Protecting Intellectual Property
Risks Related Relationships Parties S-1
S-10 S-11
S-12 S-13
S-14 S-15
S-16 S-17
S-18 S-19
S-2 S-22
S-23 S-24
S-25 S-26
S-27 S-28
S-29 S-30
S-34 S-35
S-36 S-4
S-5 S-6
S-8 S-9
Safe Harbor Sale Substantial Number Shares Adversely Affect Market Price
Sale Substantial Number Shares Including Become Eligible Near Sales Similar Securities
Sarbanes-oxley Act 2002 Satisfaction Discharge Defeasance
Schedule 522 Schedule 711
Schedule Investors Scientific Consultants
Securities Authorized Issuance Equity Compensation Plans Securities Exchange
Securities Registered Pursuant Act Securities Registered Pursuant Act Common Stock 0001 Par
Security Ownership Certain Beneficial Owners Management See Accompanying Notes
See Reverse Side Meeting Information Instructions Vote Segment Information
Selected Quarterly Financial Information Severance Plan
Share Purchase Rights Plan Signature
Signature Page Follows Signatures
Skin Solicitation Voting Proxies
Some Competitors Develop Technologies Superior Cost-effective Ours Impact Start Licensing Inc
Start Licensing Viagen Inc Statement Cash Flows Data
Stem Cells Stock Available Issuance
Stock Based Compensation Stock Issuances
Stock Option Committee Stock Option Plan
Stock Price Historically Been Very Volatile Stock Subject Plan
Stock-based Compensation Stock-based Compensation Service Providers
Stockholder Approval Stockholder Nominations Proposals 2006 Annual Meeting
Stockholder Nominations Proposals 2008 Annual Meeting Stockholder Nominations Proposals 2009 Annual Meeting
Stockholder Nominations Proposals 2010 Annual Meeting Stockholder Rights
Stockholders Equity Stockholders Equity Vendor Stock Issuances
Strategy Subject Infringement Claims Costly Defend Limit Ability Disputed
Subject Litigation Costly Defend Pursue Uncertain Outcome Submission Matters Vote Security Holders
Subordinated Debt Securities Subsequent Event
Subsequent Events Subsequent Events 2008
Successful Product Candidates Accepted Health Care Community Very Successful Products Accepted Health Care Community Very Slow
Summary 1996 Employee Stock Purchase Plan Summary 2006 Directors Stock Option Plan
Superseding Plan Survival Representations Indemnification
Switzerland Table Contents
Tax Account Implications Executive Compensation Telomerase Activation
Telomerase Inhibition Telomerase Inhibition Grn163l
Telomerase Inhibitors Telomerase Therapeutic Vaccine
Telomerase Therapeutic Vaccine Grnvac1 Telomerase Therapeutic Vaccine Program
Telomeres Telomerase Role Cellular Aging Cancer Telomeres Telomerase- Background
Term Options Term Plan Effective Date
Termination Purchase Rights Terms Awards
Therapeutic Applications Using Hescs Therapeutics Ltd
Third-party Beneficiaries Thomas Kiley Esq
Thomas Okarma Phd Time Granting Awards
Transfer Agent Registrar Transferability
Transgenic Animals Triggering Event
Unable Identify Safe Effective Inhibitor Telomerase Prevent Developing Underwriting
Undesignated Preferred Stock Inhibit Potential Acquisition Bids Adversely United Kingdom
United States Securities Exchange Washington 20549 Form 10-k Unrealized Gain Loss Derivatives
Unrealized Gain Loss Fair Value Derivatives Unrealized Gain Loss Fair Value Warrants Purchase Common
Unregistered Sale Equity Securities Unregistered Sales Equity Securities Proceeds
Valuation Valuation Equity Financing Warrants
Valuation Equity Instruments Valuation Equity-based Compensation
Valuation Expense Information Sfas 123r Value Received Viagen Inc
Vendor Stock Issuance Vendor Stock Issuances
Vitro Vivo
Voting Via Internet Telephone Warrant Modification
Warrants Warrants Issued Connection Equity Financings
Warrants Purchase Common Stock Washington 20549
Wish Withhold Authority Vote Individual Nominee Strike Line Witness Whereof
Wwwproxyvotecom Xenotransplantation
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki